A. Ventricular weight/ body weight (g/Kg) was not different between the groups at 3 months (P=0.26). Left ventricular scar size was also similar after Ad.SCF (16.4 ± 5.5%) and Ad.β-gal injection (18.0 ± 4.4%, P = 0.61). B. Wall motion score index, an echocardiographic estimate of infarct size, was similar between the groups at 1 week which suggests similar scar size before the gene transfer (Ad.SCF, 2.01±0.16 vs Ad.β-gal, 2.01±0.56, P=0.98), whereas it was lower in the Ad.SCF group 3 months after the gene delivery without statistical significance (Ad.SCF, 1.68±0.40 vs Ad.β-gal, 1.99±0.36, P=0.18).